synergy nash tirzepatide Nearly 62% achieve MASH resolution without worsening of fibrosis with PDF) Randomised clinical trial: Design

Within months of GLP-1 prescriptions written for obesity and overweight, JP Morgan analysts wrote an influential report on the drug category and implications for the health care industryand other sectors, notably food and beverage consumption

A common cold shouldn't automatically stop your tirzepatide therapy, but timing and symptoms matter

ELISA Assays: Overlapping binding causes misinterpretations if controls are insufficient

Oral anti-hyperglycemic medications, other than sulfonylureas and SGLT2 inhibitors, provide a reasonable alternative to insulin and can be continued safely perioperatively depending upon the type of surgery and the patient is expected to resume oral intake soon postoperatively.

Diabetes is prevalent worldwide and the number of patients is drastically rising, with a predication of 366 million in 2030 due to factors such as obesity, inactivity,

The pill era has ushered in a Wild-West-style land-grab for GLP-1 market share but the horizon seems to keep expanding.